Theralase Technologies Inc. · TSXV:TLT
Theralase Technologies — Investor Presentation (June 2022)
20 slides from Theralase Technologies's investor presentation, Jun 28, 2022
Slide 1: Clinical Stage Pharmaceutical Company
Clinical Stage Pharmaceutical Company Focused on the commercialization of light activated Photo Dynamic Compounds (“PDCs”) for bladder cancer June 28, 2022 TSXV:TLT / OTCQB:TLTFF
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements (“FLS”) contained in this presentation deal with the future revenue potential, business opportunities and/or strategic initiatives of Theralase® Technologies Inc. (“Theralase®” or the “Company”); including: information, analyses and/or projection
Slide 3: Company
Company Scientific Clinical Proof Pipeline Experience Intellectual Research Primary Extensive pharmaceutical Property Phase Ib Non-Muscle Invasive NMIBC 3 research, drug development, Patented light-activated Bladder Cancer (“NMIBC”) manufacturing, 42 issued patents for its PDC Photo Dynamic Compound
Slide 4: TLD-1433
TLD-1433 • Ruthenium based PDC • Potential to destroy solid core tumours, such as bladder, brain, lung and breast 9 • Preferentially absorbed into bladder cancer cells, leaving healthy urothelial cells intact 10 • Pivotal Phase II NMIBC clinical study for patients with BCG-Unresponsive Carcinoma In-
Slide 5: Mechanism of Action
Mechanism of Action 14 TLD-1433 Transferrin (Tf) + TLD-1433 Light (Visible or NIR) = Rutherrin® Transferrin (Tf) TfR TfR Transferrin Receptor (“TfR”) TfR TLD-1433 Retained TfR 1O 2 ROS TfR TLD-1433 TfR Cancer Cell Cancer Cell Cancer Cell Destruction via Immunogenic Cell Death (“ICD”) TfR TLD-1433 Qu
Slide 6: NMIBC
NMIBC 243,000 New patients diagnosed with bladder cancer each year (United States, Canada and Europe) 15 170,000 Non-Muscle Invasive 70% Patients treated with intravesical Bacillus Calmette- Bladder Cancer Guérin (“BCG”) standard of care treatment 16 (“NMIBC”) 51,000 Muscle Invasive Patients recur w
Slide 7: NMIBC Market Opportunity
NMIBC Market Opportunity Patients willing to pay between $USD Social 50,000 to $USD 150,000 per Quality $1.1 23 to 1.7 15, 16, 17, 20, 24 Demand Adjusted Life Year (“QALY”) for treatment Billion Annually (Average = $USD 100,000) 20 Innovation Bladder cancer patients face low Quality 243,000 15 x 70%
Slide 8: Study Treatment
Study Treatment TLD-1433 instilled in bladder via catheter 25 TLD-1433 localizes preferentially inside bladder cancer cells 26, 27 25 Phase Ib NMIBC clinical study patient cystoscopy photograph, after instillation of Study Drug, prior to TLC-3200 Light Activation, showing TLD-1433 localization to bl
Slide 9: Study Treatment
Study Treatment Green laser light activates TLD-1433 through fiber optics Bladder cancer cells destroyed by the production of singlet oxygen and / or Reactive Oxygen Species (“ROS”) 26 25 Phase Ib NMIBC clinical study patient cystoscopy photograph, after instillation of Study Drug, prior to TLC-3200
Slide 10: Phase II NMIBC Clinical Study Design
Phase II NMIBC Clinical Study Design 25 FDA Guidelines state that Primary Objective Secondary Objective Tertiary Objective “In BCG-Unresponsive NMIBC, a single-arm clinical trial with Complete Response (“CR”) rate and duration of response as the Initial Efficacy Duration of Efficacy Safety primary e
Slide 11: Phase II NMIBC Preliminary Clinical Data
Phase II NMIBC Preliminary Clinical Data Assessment 90 Day 180 Day 270 Day 360 Day 450 Day Complete Response (“ CR ”) 46% 50% 39% 22% 23% Partial Response (“ PR ”) 22% 22% 8% 17% 9% Total Response (“ CR + PR ”) 68% 72% 46% 39% 32% Note: The data analysis is only a representation of the data accrued
Slide 12: Phase II NMIBC Clinical Study Timeline (Projected)
Phase II NMIBC Clinical Study Timeline (Projected) 100 to 125 Patients Treated (Projected) Fast Track Designation 6 Breakthrough Designation (Projected) Patient Follow Up (Projected) 34 Press Release - Theralase Announces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical
Slide 13: Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (“NSCLC”) Non-Small Cell Lung Cancer - Rutherrin® + X-Ray Activation Rutherrin® + X-Ray Activation leads to a 3 log kill of human NSCLC cells in-vitro 36 Kaspler, P, Roufaiel, M, Mandel, A. Theralase Research Paper June 20, 2021 13
Slide 14: GlioBlastoma Multiforme (GBM)
GlioBlastoma Multiforme(“GBM”) 14
Slide 15: Virus Vaccine Research and Development
Virus Vaccine Research and Development Primary: TLD-1433 has the ability to inactivate enveloped viruses by up to 6 log kill in-vitro an nanomolar concentrations, thus allowing the manufacture of a wholly-inactivated vaccine for H1N1 Influenza, Zika, Herpes Simplex and Corona viruses - Biological Sa
Slide 16: Management Team
Management Team Arkady Mandel Kristina Hachey Vera Madzarevic M.D., Ph.D., D.Sc. CPA Ph.D. Interim Chief Executive Officer and Chief Scientific Officer Chief Financial Officer Director of Clinical Development and Quality Assurance 30+ years of scientific, 20+ years of financial and preclinical and c
Slide 17: Board of Directors
Board of Directors Arkady Mandel Kristina Hachey Guy Anderson Matthew Perraton Randy Bruder M.D., Ph.D., D.Sc. MDA, CFP®, CIM® Interim Chief Executive Officer CPA PFP, FMA, FCSI 30+ years of senior & Chief Financial Officer 20+ years of financial 20+ years of financial Chief Scientific Officer manag
Slide 18: Capital Structure
Capital Structure TSXV:TLT Date: 06/27/2022 Common share price $CAN 0.345 Warrants 67,768,615 Market Capital $CAN 70.9 M Options 10,440,000 Insider Shares Outstanding 204,425,875 ~ 10% Ownership Research Capital $CAN 01.20 – Research Capital Analyst Coverage Echelon Wealth Target Price $CAN 0.50 - E
Slide 19: Company
Company Scientific Clinical Proof Pipeline Experience Intellectual Research Primary Extensive pharmaceutical Property Phase Ib Non-Muscle Invasive NMIBC 3 research, drug development, Patented light-activated Bladder Cancer (“NMIBC”) manufacturing, 42 issued patents for its PDC Photo Dynamic Compound
Slide 20: Contact Information
Contact Information Akanksha Dhingra, Public Relations and Investor Relations Coordinator - [email protected] x 303 Kristina Hachey, Chief Financial Officer - [email protected] x 224 Arkady Mandel, Interim Chief Executive Officer / Chief Scientific Officer - [email protected] x 260 Toll
Theralase Technologies — Investor Presentation (June 2022) on 6ix